Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users

被引:6
|
作者
Coupland, Heidi [1 ,2 ]
Day, Carolyn [3 ]
Levy, Miriam T. [4 ,5 ]
Maher, Lisa [2 ]
机构
[1] Univ New S Wales, St Vincents Med Ctr, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[2] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia
[3] Univ Sydney, Cent Clin Sch, Sydney Med Sch, Sydney, NSW 2006, Australia
[4] Univ New S Wales, S Western Sydney Area Hlth Serv, Sydney, NSW, Australia
[5] Univ New S Wales, Fac Med, Sydney, NSW, Australia
关键词
injecting drug user; hepatitis C treatment; marginalisation; cultural diversity; VIRUS HCV INFECTION; BLOOD-BORNE VIRUSES; ETHNIC-VIETNAMESE; RISK BEHAVIORS; BARRIERS; THERAPY; EPIDEMIOLOGY; MELBOURNE; KNOWLEDGE; ATTITUDES;
D O I
10.1071/HE09234
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Issue addressed: Increasing the uptake of hepatitis C treatment by injecting drug users (IDUs) is a key strategy in addressing the escalating disease burden of chronic hepatitis C virus (HCV) infection in Australia. Little is known about barriers to treatment uptake among culturally diverse groups of IDUs. Indo-Chinese IDUs represent a marginalised group with high rates of incident and prevalent HCV infection. Methods: An ethnographic study was conducted to explore barriers to HCV treatment uptake experienced by Indo-Chinese IDUs and inform the development of policies and practices that promote access to treatment. Following a baseline interview, participants (n=23) received a brief intervention about HCV treatment and an offer of facilitated referral to a tertiary liver clinic. Follow-up interviews were conducted three and six months post intervention, to explore decision-making about treatment-seeking and experiences accessing the clinic. Results: While 'getting rid of' HCV was regarded as highly desirable, only three participants were assessed for treatment. For most participants, seeking treatment was not seen as feasible given social and structural barriers related to their drug use, lack of resources and support. Institutional barriers included the clinic's administrative procedures, limited flexibility and apparent reluctance to consider current IDUs suitable candidates for treatment. Conclusions: Resources and support, flexible, low threshold approaches to assessment and a willingness to provide treatment to current IDUs, would promote equitable access to treatment among these groups.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 50 条
  • [21] The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users
    Murray, JM
    Law, MG
    Gao, ZH
    Kaldor, JM
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2003, 32 (05) : 708 - 714
  • [22] Hepatitis C virus infection among injecting drug users in the Czech Republic - Prevalence and associated factors
    Zabransky, Tomas
    Mravcik, Viktor
    Korcisova, Blanka
    Rehak, Vratislav
    EUROPEAN ADDICTION RESEARCH, 2006, 12 (03) : 151 - 160
  • [23] Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human immunodeficiency virus
    Anna Gyarmathy, V.
    Neaigus, Alan
    Li, Nan
    Ujhelyi, Eszter
    Caplinskiene, Irma
    Caplinskas, Saulius
    Latkin, Carl A.
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 43 (01) : 32 - 42
  • [24] Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness
    Korthuis, P. Todd
    Feaster, Daniel J.
    Gomez, Zoilyn L.
    Das, Moupali
    Tross, Susan
    Wiest, Katharina
    Douaihy, Antoine
    Mandler, Raul N.
    Sorensen, James L.
    Colfax, Grant
    McCarty, Dennis
    Cohen, Stephanie E.
    Penn, Patricia E.
    Lape, Diane
    Metsch, Lisa R.
    ADDICTIVE BEHAVIORS, 2012, 37 (04) : 552 - 555
  • [25] Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City
    Howe, CJ
    Fuller, CM
    Ompad, DC
    Galea, S
    Koblin, B
    Thomas, D
    Vlahov, D
    DRUG AND ALCOHOL DEPENDENCE, 2005, 79 (03) : 389 - 395
  • [26] HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran
    Rahimi-Movaghar, Afarin
    Razaghi, Emran M.
    Sahimi-Izadian, Elaheh
    Amin-Esmaeili, Masoumeh
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 (01) : E28 - E33
  • [27] Perceptions of drug users regarding Hepatitis C screening and care: a qualitative study
    Jordan, Ashly E.
    Masson, Carmen L.
    Mateu-Gelabert, Pedro
    McKnight, Courtney
    Pepper, Nicole
    Bouche, Katie
    Guzman, Laura
    Kletter, Evan
    Seewald, Randy M.
    Des-Jarlais, Don C.
    Sorensen, James L.
    Perlman, David C.
    HARM REDUCTION JOURNAL, 2013, 10
  • [28] Identification and phylogenetic analysis of hepatitis C virus in forensic blood samples obtained from injecting drug users
    Kato, H.
    Maeno, Y.
    Seko-Nakamura, Y.
    Monma-Ohtaki, J.
    Sugiura, S.
    Takahashi, K.
    Zhe, L. X.
    Matsumoto, T.
    Kurvanov, F.
    Mizokami, M.
    Nagao, M.
    FORENSIC SCIENCE INTERNATIONAL, 2007, 168 (01) : 27 - 33
  • [29] Current Situation and Trends in the Hepatitis C Virus Genotype Distribution among Injecting Drug Users in the Czech Republic
    Krekulova, L.
    Rehak, V
    Strunecky, O.
    Nemecek, V
    EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE, 2009, 58 (02): : 84 - 89
  • [30] Exploration of genetically determined resistance against hepatitis C infection in high-risk injecting drug users
    Sugden, P. B.
    Cameron, B.
    Luciani, F.
    Lloyd, A. R.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (08) : E65 - E73